SBFM — Sunshine Biopharma, Inc.
$0.1500-10.18%
Last close: · regular session
Last 60 sessions
SBFM closed at $0.1500 (-10.18%) on Oct 23, 2026. Recent offering filing (424B3, Sep 2026). Float: 4.9M shares. Latest SEC filing: 8-K on Sep 16, 2026.
Opening the full analysis uses 1 of your 3 free tickers today.
Chart, dilution, float and news for SBFM in the TickerWise workspace.
Sunshine Biopharma, Inc. operates as a pharmaceutical entity and a provider of nutritional supplements, primarily dedicating its efforts to the research and development of novel anticancer therapies. A key pipeline candidate is Adva-27a, a GEM-difluorinated C-glycoside derivative of podophyllotoxin, designed to combat a broad spectrum of malignancies, including leukemia, lymphoma, testicular, lung, brain, prostate, bladder, colon, ovarian, and liver cancers. Notably, Adva-27a also demonstrates efficacy against multidrug-resistant cancer cells, encompassing pancreatic, breast, small-cell lung, and uterine sarcoma cells. The company is also progressing SBFM-PL4, a compound under development as an anti-coronavirus treatment. In addition to its drug development, Sunshine Biopharma markets a range of nutritional products, such as the Essential 9 tablet and the Essential Calcium-Vitamin D supplement, alongside other scientifically formulated dietary aids. A collaboration with the University of Georgia supports the ongoing advancement of SBFM-PL4 as an anti-coronavirus agent. The firm's headquarters are situated in Pointe-Claire, Canada.
Company profile
- Sector: Healthcare
- Industry: Drug Manufacturers - Specialty & Generic
- Country: US
- Exchange: NASDAQ Capital Market
- Employees: 52
- Website: https://www.sunshinebiopharma.com
Latest SEC filings for SBFM
Latest SBFM news
- Sunshine Biopharma announces reverse stock split to maintain Nasdaq listing Read article
- Sunshine Biopharma Announces Closing of up to $20.4 Million Public Offering Read article
- Sunshine Biopharma announces pricing of $6M public offering Read article
- Sunshine Biopharma Inc. Announces Pricing of $6.0 Million Public Offering Read article
- Sunshine Biopharma Soars as Traders Appear to Chase a Speculative Rebound
- Warrants for 200,000 shares feature in Alta’s amended Sunshine Biopharma (SBFM) stake report.
- Sunshine Biopharma (SBFM) Retreats 11% to $0.69 as Shares Approach Key Support
Related companies
Opening the full analysis uses 1 of your 3 free tickers today.
Educational tool only — not investment advice.